COVID-19: INTRAPULMONARY ALKALINE HYDROGEN PEROXIDE CAN IMMEDIATELY INCREASE BLOOD OXYGENATION

  • Aleksandr Urakov Izhevsk State Medial Academy
  • Evgeniy Fisher
  • Milena Svetova
  • Darya Suntsova
  • Ilnur Yagudin

Sažetak


It has been shown that the new coronavirus infection is life-threatening for patients not because of the COVID-19 virus, but because of the complications it causes. The most dangerous complication of this disease is the airway obstruction syndrome, which occurs with atypical pneumonia. Blockage of the airways occurs due to the accumulation of excessively large amounts of mucus and pus in them and swelling of the lung tissue, so ventilation of the lungs with air becomes almost impossible.  The sad outcome of respiratory obstruction is hypoxia and hypoxic brain damage. Under these conditions, extracorporeal membrane oxygenation remains the only known way to increase blood oxygenation. However, in 2021, it was shown that intra-pulmonary administration of a warm alkaline solution of hydrogen peroxide immediately turns mucus and pus into oxygen foam and increases blood oxygen saturation. The proposed technology is a new variant of emergency blood oxygenation in severe suffocation caused by blockage of the respiratory tract with mucus, pus and blood.

Reference


  1. Wunsch H. Mechanical ventilation in COVID-19: Interpreting the current epidemiology. American Journal of Respiratory and Critical Care Medicine. 2020;202(1):1-4.

  2. Pappalardo F, Crivellari M. Predicting outcome of venovenous ECMO: look outside the lung! Journal of Thoracic Disease. 2018;10(3):1356–60.

  3. Harvey MJ, Gaies MG, Prosser LA. U.S. and international in-hospital costs of extracorporeal membrane oxygenation: a systematic review. Applied Health Economics and Health Policy. 2015;3(4):341–57.

  4. Parrilla FJ, Morán I, Roche-Campo F. et al. Ventilatory strategies in obstructive lung disease. Seminars in Respiratory and Critical Care Medicine. 2014;35(4):431-40.

  5. Urakov A, Urakova N. Recent Insights into the Management of Inflammation in Asthma [Letter]. J Inflamm Res. 2021;(14):4603-04.

  6. Urakov A, Urakova N, Reshetnikov A. Oxygen alkaline dental's cleaners from tooth plaque, food debris, stains of blood and pus: A narrative review of the history of inventions. Journal of International Society of Preventive & Community Dentistry. 2019;9(5):427-33.

  7. Urakov AL, Urakova NA. COVID-19: Optimization of respiratory biomechanics by aerosol pus solvent. Russian Journal of Biomechanics. 2021;25(1):86-90.

  8. Urakov AL, Yagudin II, Suntsova DO, Svetova MD, Stolyarenko AP. COVID-19: Thick Pus, Mucus and Sputum with Streaks of Blood as a Cause of Airway Obturation in SARS and Oxygen-Foaming Pus Solvent as a Medicine for their Recanalization. Acta Scientific Women's Health. 2021;3(5):75-7.

  9. Urakov AL, Urakova NA, Yagudin II, Svetova MD, Suntsova DO. COVID-19: Artificial sputum, respiratory obstruction method and screening of pyolytic and antihypoxic drugs. Bioimpacts. 2022;12 (in press).

  10. Kurukulaaratchy RJ, Rupani H, Fong WCG, Kyyaly A. A Role for Mucolytics and Expectorants in Aiding Inhaled Therapies in Asthma? [Response To Letter], J Inflamm Res. 2021;14:5183-5.

  11. Bonser LR, Erle DJ. Airway mucus and asthma: the role of MUC5AC and MUC5B. J Clin Med. 2017;6(12):112-7.

  12. Morinaga Y, Yanagihara K, Miyashita N, Seki M. Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells. Pulm Pharmacol Ther. 2009;22(6):580–6.

  13. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;2019(5):CD001287.

  14. Millman M, Millman FM, Goldstein IM, Mercandetti AJ. Use of acetylcysteine in bronchial asthma–another look. Ann Allergy. 1985;54(4):294–6.

  15. Morgan LE, Jaramillo AM, Shenoy SK, et al. Disulfide disruption reverses mucus dysfunction in allergic airway disease. Nat Commun. 2021;12(1):249-53.

  16.  Juergens LJ, Worth H, Juergens UR. New perspectives for mucolytic, anti-inflammatory and adjunctive therapy with 1,8-cineole in COPD and asthma: review on the new therapeutic approach. Adv Ther. 2020;37(5):1737–53.

Objavljeno
2022/04/05
Rubrika
Pregledni članak